Cost-Effectiveness Analyses of Natalizumab (Tysabri®) Compared with Other Disease-Modifying Therapies for People with Highly Active Relapsing-Remitting Multiple Sclerosis in the UK

被引:0
作者
Ray Gani
Gavin Giovannoni
David Bates
Belinda Kemball
Steve Hughes
John Kerrigan
机构
[1] Heron Evidence Development,
[2] The Royal London Hospital,undefined
[3] Royal Victoria Infirmary,undefined
[4] Biogen Idec,undefined
[5] Heron Evidence Development,undefined
来源
PharmacoEconomics | 2008年 / 26卷
关键词
Multiple Sclerosis; Multiple Sclerosis Patient; Progressive Multifocal Leukoencephalopathy; Natalizumab; Glatiramer Acetate;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:617 / 627
页数:10
相关论文
共 110 条
[1]  
Richards RG(2002)A review of the natural history and epidemiology of multiple sclerosis: implications for resource allocation and health economic models Health Technol Assess 6 1-73
[2]  
Sampson FC(2007)The effect of disease, functional status, and relapses on the utility of people with multiple sclerosis in the UK Value Health 10 54-60
[3]  
Beard SM(2007)The distribution of the cost of multiple sclerosis in the UK: how do costs vary by illness severity? Value Health 10 386-9
[4]  
Orme M(1997)Long-term survival experience of patients with multiple sclerosis J Insur Med 29 101-106
[5]  
Kerrigan J(2003)Early clinical predictors and progression of irreversible disability in multiple sclerosis: an amnesic process Brain 126 770-782
[6]  
Tyas D(2001)Natural history of multiple sclerosis J Neurol Neurosurg Psychiatry 71 ii16-ii19
[7]  
Tyas D(1989)The natural history of multiple sclerosis: a geographically based study. 2: predictive value of the early clinical course Brain 112 1419-1428
[8]  
Kerrigan J(1999)The natural history of multiple sclerosis: a geographically based study. 5: the clinical features and natural history of primary progressive multiple sclerosis Brain 122 625-639
[9]  
Russell N(2001)Interferon in relapsing — remitting multiple sclerosis Cochrane Database Syst Rev 4 CD002002-910
[10]  
Pokorski RJ(2004)Therapy with glatiramer acetate for multiple sclerosis Cochrane Database Syst Rev 1 CD004678-1452